Stay ahead of the curve and gain valuable knowledge that can help bring a market access mindset to your commercial and development strategies.
As a follow-on to our blog, “Is Your Access Strategy Aligned?”, we now focus on one of the most critical—but often siloed—elements of BioPharma commercialization: Pricing. Many companies determine their new medicine’s price by doing a typical analog analysis whereby the price is anchored to the relative perceived value of the new medicine vs other […]
As a follow on to our recent blog series on Pricing, we will now focus a series on the critical importance of having an integrated Pricing, Contracting and Channel strategy (“PCC”). In pharmaceutical commercialization, the Value Proposition serves as the foundation for all PCC decisions. It defines the clinical and economic benefits of a therapy […]
Investing in a new medication or therapeutic area often focuses heavily on scientific evaluation—assessing efficacy, safety, and innovation. While these are critical, so is a rigorous market access assessment. Failing to focus on this imperative can undermine even the most promising scientific innovations. To succeed, manufacturers and investors must consider upfront how a therapy will overcome […]
Effectively communicating the price of a new medicine is as critical as determining the price itself. Transparent communication ensures that all stakeholders understand how the price aligns with the total value proposition. Doing this well allows your organization to focus your time and energy on what matters most, the benefits the medicine delivers to patients. […]
Pricing plays a crucial role in the success of every pharmaceutical product launch. It is essential to carefully consider the needs of various stakeholders, including payers, physicians, other providers, patients, as well as investors. Without a sophisticated pricing strategy, a BioPharma company risks damaging its reputation, facing payer restrictions, and failing to maximize revenue potential. […]
Pricing new medicines is a critical and time-consuming process. It stands as one of the most important decisions a company makes. Drug prices face constant scrutiny and criticism from various stakeholders along the value chain, including the media and politicians. The complexity of the US healthcare system, with its multiple stakeholders and diverse financial incentives, […]
Hub services are critical to the successful launch of innovative medicines. Done properly, these programs accelerate patient therapy adoption and support treatment compliance by removing unnecessary friction...
Misaligned incentives can be found everywhere across the healthcare ecosystem. Inflated list prices needed to support an arcane discounts/rebates model, intermediaries profiting from every transaction along the supply chain continuum...
Last week A3Access Advisors, LLC spent the week in San Francisco at the JP Morgan Conference. After the past few years of torrential rain, a pandemic, lackluster enthusiasm, the Silicon Valley bank debacle, and industry fatigue...